Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.606 SEK | -5.31% | -8.46% | -50.73% |
04-16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
03-08 | Transcript : Nanexa AB - Special Call |
Sales 2024 * | 71.3M 6.52M 522M | Sales 2025 * | 69.5M 6.35M 508M | Capitalization | 82.23M 7.52M 602M |
---|---|---|---|---|---|
Net income 2024 * | 16M 1.46M 117M | Net income 2025 * | -4M -366K -29.26M | EV / Sales 2024 * | 0.23 x |
Net cash position 2024 * | 65.5M 5.99M 479M | Net cash position 2025 * | 82M 7.5M 600M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
15.2
x | P/E ratio 2025 * |
2.75
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.75% |
Latest transcript on Nanexa AB
1 day | -5.31% | ||
1 week | -8.46% | ||
Current month | -21.91% | ||
1 month | -20.26% | ||
3 months | -44.40% | ||
6 months | -38.79% | ||
Current year | -50.73% |
Managers | Title | Age | Since |
---|---|---|---|
Mårten Rooth
FOU | Founder | 47 | 31/12/06 |
Anders Johansson
FOU | Founder | 48 | 31/12/06 |
David Westberg
CEO | Chief Executive Officer | 64 | 31/03/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 75 | 01/06/20 | |
Director/Board Member | 69 | 31/12/22 | |
Corporate Officer/Principal | 62 | 31/12/14 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.606 | -5.31% | 449,411 |
25/04/24 | 0.64 | -0.62% | 262,901 |
24/04/24 | 0.644 | -3.01% | 255,817 |
23/04/24 | 0.664 | +3.75% | 17,042 |
22/04/24 | 0.64 | -3.32% | 729,113 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-50.73% | 7.5M | |
-10.84% | 187M |
- Stock Market
- Equities
- NANEXA Stock